Literature DB >> 24419300

Melanoma in 2013: Melanoma--the run of success continues.

Dirk Schadendorf1, Axel Hauschild2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419300     DOI： 10.1038/nrclinonc.2013.246

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors:  Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

2.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

3.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

5.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Authors:  Alexander Roesch; Adina Vultur; Ivan Bogeski; Huan Wang; Katharina M Zimmermann; David Speicher; Christina Körbel; Matthias W Laschke; Phyllis A Gimotty; Stephan E Philipp; Elmar Krause; Sylvie Pätzold; Jessie Villanueva; Clemens Krepler; Mizuho Fukunaga-Kalabis; Markus Hoth; Boris C Bastian; Thomas Vogt; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

6.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Authors:  Kerstin Trunzer; Anna C Pavlick; Lynn Schuchter; Rene Gonzalez; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Kevin B Kim; Jeffrey S Weber; Peter Hersey; Georgina V Long; Donald Lawrence; Patrick A Ott; Ravi K Amaravadi; Karl D Lewis; Igor Puzanov; Roger S Lo; Astrid Koehler; Mark Kockx; Olivia Spleiss; Annette Schell-Steven; Houston N Gilbert; Louise Cockey; Gideon Bollag; Richard J Lee; Andrew K Joe; Jeffrey A Sosman; Antoni Ribas
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

7.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962
  9 in total
  30 in total

1.  Melanoma resistance: a bright future for academicians and a challenge for patient advocates.

Authors:  Andrzej T Slominski; J Andrew Carlson
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 2.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

Review 3.  Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.

Authors:  Esther Bastiaannet; Nicolò Battisti; Kah Poh Loh; Nienke de Glas; Enrique Soto-Perez-de-Celis; Capucine Baldini; Ellen Kapiteijn; Stuart Lichtman
Journal:  J Geriatr Oncol       Date:  2018-07-17       Impact factor: 3.599

4.  Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.

Authors:  Lawrence W Wu; Gao Zhang; Meenhard Herlyn
Journal:  Mol Cell Oncol       Date:  2016-05-02

Review 5.  What is new in computer vision and artificial intelligence in medical image analysis applications.

Authors:  Jimena Olveres; Germán González; Fabian Torres; José Carlos Moreno-Tagle; Erik Carbajal-Degante; Alejandro Valencia-Rodríguez; Nahum Méndez-Sánchez; Boris Escalante-Ramírez
Journal:  Quant Imaging Med Surg       Date:  2021-08

Review 6.  Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines.

Authors:  Jakub Dalibor Rybka
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-06

7.  Vitamin D as an adjuvant in melanoma therapy.

Authors:  Andrzej T Slominski; Anna Brozyna; Wojciech Jozwicki; Robert C Tuckey
Journal:  Melanoma Manag       Date:  2015-01-01

8.  Targeted deactivation of cancer-associated fibroblasts by β-catenin ablation suppresses melanoma growth.

Authors:  Linli Zhou; Kun Yang; R Randall Wickett; Ana Luisa Kadekaro; Yuhang Zhang
Journal:  Tumour Biol       Date:  2016-08-29

9.  The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

Authors:  A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves
Journal:  Arch Biochem Biophys       Date:  2014-07-02       Impact factor: 4.013

Review 10.  Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.

Authors:  A Roesch
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.